Phillip Davis

Phillip Davis is a clinical and regulatory leader with a background in nuclear medicine, FDA strategy, clinical development, and medical affairs, supporting the advancement of novel theranostics toward marketing authorization and clinical adoption. He spent a decade as a senior clinical reviewer at the U.S. Food and Drug Administration in the Division of Imaging and Radiation Medicine. After leaving the FDA, he joined Blue Earth Diagnostics, contributing to the development, FDA approval, and U.S. launch of a PSMA-targeted PET tracer. His current work focuses on ADC and radionuclide conjugate theranostics, as well as clinical studies and NDA preparation for rare pediatric and orphan indications.